Biofrontera Inc.: financial analysis
Ratios worked out from 7 fiscal years of Biofrontera Inc.'s statements, compared with 665 companies in Biotechnology.
Biofrontera Inc. scorecard#
Passes 10 of the 20 checks that could be worked out: strongest in growth (5 of 6), weakest in financial health (1 of 3). Fiscal year 2025; market cap of Oct 14, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median0.3×Price to sales 0.3× against Biotechnology's median of 8.8×.
- ✗Free cash flow yield above 5%-83.7%Free cash flow is -83.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 4.92% (2026-11-20).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth5 of 6
- ✓Revenue grew in the newest year11.7%Revenue up 11.7% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years13.3%13.3% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median13.3%13.3% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-1.04 vs -3.22Diluted EPS -1.04 in fiscal 2025 against -3.22 the year before (report's currency).
- ✓Net income higher than five years earlier-$11 M-$11 M in fiscal 2025 against -$11 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability2 of 5
- ✗Profitable in the newest year-$11 MNet income -$11 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median-27.2%-27.2% against Biotechnology's median of -60.5% (243 companies).
- ✗Return on equity above 15%-141.4%-141.4% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-27.2%-27.2% in fiscal 2025 against -64.8% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.52 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-5.33Z-score -5.33 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year84.4%Diluted shares up 84.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Revenue has grown 5 years in a row.
Worth a look
- Net loss of $11 million, the 6th loss-making year in a row.
- Free cash flow was negative: -$13 million.
- The share count rose 84.4% in the year.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseyes
- Cash from operations exceeds profitno
- Long-term debt fell against assetsnot on file
- Current ratio roseno
- No new shares issuedno
- Gross margin rosenot on file
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.22 | × 1.2 | 0.26 |
| Retained earnings to assets | -4.48 | × 1.4 | -6.27 |
| Operating income to assets | -0.40 | × 3.3 | -1.31 |
| Market value to liabilities | 0.88 | × 0.6 | 0.53 |
| Revenue to assets | 1.46 | × 1 | 1.46 |
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -27.2% | -46.1% | -66.6% | -64.8% | -104.6% | -60.5% | 60% | |
| Net margin | -25.3% | -47.6% | -59.1% | -2.2% | -156.5% | -68.9% | 60% | |
| Return on equity | -141.4% | -385.3% | -140.4% | -3.6% | -439.3% | -61.0% | 22% | |
| Return on assets | -41.6% | -71.0% | -51.1% | -1.2% | -97.5% | -44.4% | 54% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 11.7% | 9.5% | 18.8% | 19.0% | 27.9% | 15.8% | 46% | |
| Revenue growth, 3 years a year | 13.3% | 15.7% | 21.8% | — | — | 12.9% | 51% | |
| Revenue growth, 5 years a year | 17.2% | — | — | — | — | 15.4% | 55% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Interest cover | — | — | -103.09× | — | -74.12× | -22.77× | — | |
| Current ratio | 1.52× | 1.72× | 1.28× | 2.07× | 3.35× | 4.39× | 18% | |
| Equity share of assets | 36.7% | 20.1% | 17.2% | 46.9% | 21.3% | 64.7% | 31% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-13 M | $-10 M | $-25 M | $-16 M | — | $-40 M | 71% | |
| Free cash flow margin | -32.0% | -27.6% | -73.1% | -56.6% | — | -61.5% | 58% | |
| Capital spending share of revenue | 0.0% | 0.0% | 0.0% | 0.1% | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 1.65× | 1.49× | 0.86× | 0.55× | 0.62× | 0.26× | 99% |
How each figure is worked out#
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).